Chiesi Global Rare Diseases and Protalix BioTherapeutics … – BioSpace
PEGylated enzyme replacement therapy designed to provide a long half-life
PARMA, Italy, BOSTON and CARMIEL, Israel, May 5, 2023 /PRNewswire/ -- Chiesi Global Rare Diseases, a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases, and Protalix BioTherapeutics, Inc. (NYSE American:PLX), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx, today announced that the European Commission (EC) has granted marketing authorization to PRX-102 (pegunigalsidase alfa) in the European Union (EU) for the treatment of adult patients with Fabry disease.
"People living with Fabry disease often perceive their disease as burdensome and still experience unmet medical needs," said Giacomo Chiesi, head of Chiesi Global Rare Diseases. "Our deepest gratitude to all patients and patient advocates who have stood shoulder-to-shoulder with clinical researchers, scientists and regulators during the clinical development program, providing the data needed for this approval. I believe this is a vital ingredient in bringing innovation to the real lives of patients and enabling hope and definitive, integrated solutions."
"We are delighted that the European Commission has approved PRX-102 for the treatment of adult patients with Fabry disease. The EU authorization is a testament to our commitment to deliver innovative therapies and solutions for people affected by rare diseases," said Diego Ardig, M.D., Ph.D., head of research and development of Global Rare Diseases at the Chiesi Group. "As a certified B Corp we are committed to ensuring access to PRX-102 to as many people living with Fabry disease as possible and thank those who participated in our extensive clinical research program. It is important to deliver this new treatment option to reduce the burden of this chronic disease on patients, their families, and the healthcare system."
"The European Commission's approval of PRX-102 is a significant milestone for patients with Fabry disease and their families, providing a new therapeutic option," said Dror Bashan, Protalix's President and Chief Executive Officer. "We are proud of this achievement and believe that this approval further validates our science and technology. Based on solid results from our robust clinical programs, PRX-102 has the potential to be widely used for many years to come. Together with Chiesi, we remain committed to meeting the needs of patients with Fabry disease and bringing this new treatment option to market."
PRX-102 is a PEGylated enzyme replacement therapy (ERT). It is a recombinant human GalactosidaseA enzyme expressed in plant-cell culture that is designed to provide a long half-life.
The EC authorization of PRX-102 is based on results from a comprehensive clinical development program in more than 140 patients with up to 7.5 years of treatment. It has been studied in both ERT-nave and ERT-experienced patients, including a head-to-head trial that met its primary endpoint, with PRX-102 demonstrating non-inferior efficacy to agalsidase beta in controlling kidney disease as evaluated by the estimated glomerular filtration rate (eGFR) decline.
Pegunigalsidase alfa, an investigational new drug product, is currently not approved by the U.S. Food and Drug Administration (FDA). The effectiveness and safety of pegunigalsidase alfa is under review, but has not yet been approved, by the FDA. Prior to FDA review and approval, no conclusions can be drawn on pegunigalsidase alfa's efficacy and safety profile. When seeking expanded access, treating physicians should consider all possible risks of treatment with pegunigalsidase alfa. Access must be compliant with all applicable federal and state laws and regulations. Investigators should not seek reimbursement for product provided to patients who participate in a government funded insurance program.
About Fabry Disease
Fabry disease is an Xlinked inherited disease that results from deficient activity of the lysosomal GalactosidaseA enzyme resulting in progressive accumulation of abnormal deposits of a fatty substance called globotriaosylceramide (Gb3) in the lysosomes throughout a person's body. Fabry disease occurs in one person per 40,000 to 60,000. Fabry patients inherit a deficiency of the GalactosidaseA enzyme, which is normally responsible for the breakdown of Gb3. The abnormal storage of Gb3 increases with time and, accordingly, Gb3 accumulates, primarily in the blood vessel and tissues. The ultimate consequences of Gb3 deposition range from episodes of pain and impaired peripheral sensation to end-organ failure.
About PRX102
PRX102 (pegunigalsidase alfa) is a PEGylated enzyme replacement therapy (ERT) to treat Fabry disease that is now approved by the European Medicines Agency (EMA) and is under evaluation by the FDA. PRX-102 is a plant cell culture-expressed, and chemically modified stabilized recombinant version of the GalactosidaseA enzyme. Protein sub-units are covalently bound via chemical cross-linking using short PEG moieties, resulting in a molecule with stable pharmacokinetic parameters. In clinical studies, PRX102 has been observed to have a circulatory half-life of approximately 80 hours.
About Chiesi Global Rare Diseases
Chiesi Global Rare Diseases is a business unit of the Chiesi Group established to deliver innovative therapies and solutions for people affected by rare diseases. As a family business, Chiesi Group strives to create a world where it is common to have a therapy for all diseases and acts as a force for good, for society and the planet. The goal of the Global Rare Diseases unit is to ensure equal access so as many people as possible can experience their most fulfilling life. The unit collaborates with the rare disease community around the globe to bring voice to underserved people in the health care system.
For more information visit http://www.chiesirarediseases.com.
About Chiesi Group
Chiesi is an international, research-focused biopharmaceuticals group that develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company's mission is to improve people's quality of life and act responsibly towards both the community and the environment.
By changing its legal status to a Benefit Corporation in Italy, the US, and France, Chiesi's commitment to create shared value for society as a whole is legally binding and central to company-wide decision-making. As a certified B Corp since 2019, we're part of a global community of businesses that meet high standards of social and environmental impact. The company aims to reach Net-Zero greenhouse gases (GHG) emissions by 2035.
With over 85 years of experience, Chiesi is headquartered in Parma (Italy), operates in 31 countries, and counts more than 6,500 employees. The Group's research and development centre in Parma works alongside 6 other important R&D hubs in France, the US, Canada, China, the UK, and Sweden.
For further information please visit http://www.chiesi.com.
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain FDA approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights.
Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: pegunigalsidase alfa, a modified stabilized version of the recombinant human -Galactosidase-A protein for the treatment of Fabry disease; PRX-115, a plant cell-expressed recombinant PEGylated uricase for the treatment of severe gout; PRX-119, a plant cell-expressed long action DNase I for the treatment of NETs-related diseases; and others. Protalix has partnered with Chiesi Farmaceutici S.p.A., both in the United States and outside the United States, for the development and commercialization of pegunigalsidase alfa.
Protalix's Forward-Looking Statements
To the extent that statements in this press release are not strictly historical, all such statements are forward-looking, and are made pursuant to the safe-harbor provisions of the Private Securities Litigation Reform Act of 1995. The terms "expect," "anticipate," "believe," "estimate," "project," "may," "plan," "will," "would," "should" and "intend," and other words or phrases of similar import are intended to identify forward-looking statements. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual future experience and results to differ materially from the statements made. These statements are based on Protalix's current beliefs and expectations as to such future outcomes. Factors that might cause material differences include, among others: risks related to the timing, progress and likelihood of final approval by the FDA of the resubmitted Biologics License Application (BLA) by the PDUFA action date, if at all, and, if approved, whether the FDA will impose significant limitations on the use of PRX102; risks related to the commercial success of PRX-102, and of Protalix's other product and product candidates, if approved; the likelihood that the FDA, EMA or other applicable health regulatory authorities will approve an alternative dosing regimen; failure or delay in the commencement or completion of preclinical studies and clinical trials of our other product candidates which may be caused by several factors, including: slower than expected rates of patient recruitment; unforeseen safety issues; determination of dosing issues; lack of effectiveness during clinical trials; inability to satisfactorily demonstrate non-inferiority to approved therapies; inability or unwillingness of medical investigators and institutional review boards to follow our clinical protocols; and inability to monitor patients adequately during or after treatment; delays in the approval or potential rejection of any applications we file with the FDA, EMA or other health regulatory authorities for our other product candidates, and other risks relating to the review process; risks associated with the novel coronavirus disease, or COVID19, outbreak, which may adversely impact our business, preclinical studies and clinical trials; the risk that the results of the clinical trials of our product candidates will not support the applicable claims of safety or efficacy, or that our product candidates will not have the desired effects or will be associated with undesirable side effects or other unexpected characteristics; risks related to our ability to maintain and manage our relationship with our collaborators, distributors or partners; our dependence on performance by third party providers of services and supplies, including without limitation, clinical trial services; the inherent risks and uncertainties in developing drug platforms and products of the type we are developing; the impact of development of competing therapies and/or technologies by other companies and institutions; potential product liability risks, and risks of securing adequate levels of product liability and other necessary insurance coverage; and other factors described in our filings with the U.S. Securities and Exchange Commission. The statements in this press release are valid only as of the date hereof and we disclaim any obligation to update this information, except as may be required by law.
Chiesi Group Media ContactChiara TravaginRare Communication ManagerTel: +39 348 8818985Email c.travagin@chiesi.com
Alessio PappagalloPress Office ManagerTel: +39 339 5897483Email a.pappagallo@chiesi.com
Adam DaleyBerry & Company Public Relations1-212-253-8881adaley@berrypr.com
Protalix Investor ContactChuck Padala, Managing DirectorLifeSci Advisors646-627-8390chuck@lifesciadvisors.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/chiesi-global-rare-diseases-and-protalix-biotherapeutics-announce-european-commission-authorization-of-prx-102-pegunigalsidase-alfa-for-the-treatment-of-fabry-disease-301817012.html
SOURCE Chiesi Global Rare Diseases; Protalix BioTherapeutics, Inc.
Company Codes: AMEX:PLX
See the rest here:
Chiesi Global Rare Diseases and Protalix BioTherapeutics ... - BioSpace
- Cody Mills, 26, and Lukas Blum, LLM 26, Receive Kouba Prize for Papers on European Union Law and International Peace and Security - University of... - November 13th, 2026 [November 13th, 2026]
- Emissions trading system: Council and Parliament agree to boost free carbon allowances for energy-intensive industries - Council, European Union - November 13th, 2026 [November 13th, 2026]
- Opening remarks by President Antnio Costa at the meeting of the European Political Community in Dublin - Council, European Union - November 13th, 2026 [November 13th, 2026]
- 'Ukraine's future is within the European Union' Irish PM aims to open all EU negotiation clusters for Kyiv by end of year - The Kyiv Independent - November 13th, 2026 [November 13th, 2026]
- Fisheries and aquaculture: Council and Parliament agree on modernised framework for statistics - Council, European Union - November 13th, 2026 [November 13th, 2026]
- Matryoshka Targets Spain: How the Kremlin Uses Economic Anxiety, Separatism, and Forged Media to Weaken the European Union - Robert Lansing Institute - November 13th, 2026 [November 13th, 2026]
- Film reviews: At European Union Film Festival, difficult decisions, jet-black comedy, and hard truths - Stir - November 13th, 2026 [November 13th, 2026]
- Submission to Request for Comments on the Effect of the European Union's Carbon Border Adjustment Mechanism, Office of the United States Trade... - November 7th, 2026 [November 7th, 2026]
- Joint Communiqu: Seventeenth (17th) Annual Joint Consultative Meeting Between The African Union Peace And Security Council And The European Union... - November 7th, 2026 [November 7th, 2026]
- Enlargement is getting real: Is the EU ready? - European Union Institute for Security Studies | - November 7th, 2026 [November 7th, 2026]
- European Union awards top rights prize to International Criminal Court days after Trump sanctions - The Boston Globe - October 24th, 2026 [October 24th, 2026]
- How flexible are European Union governments willing to be to facilitate further enlargement? - Bruegel - October 24th, 2026 [October 24th, 2026]
- Britain cannot deal effectively with geopolitical crises without rejoining EU, says thinktank | European Union - The Guardian - October 24th, 2026 [October 24th, 2026]
- European Union awards top rights prize to International Criminal Court days after Trump sanctions - CoastTV - October 24th, 2026 [October 24th, 2026]
- European Union awards top rights prize to International Criminal Court days after Trump sanctions - New Castle News - October 24th, 2026 [October 24th, 2026]
- DECLARATION | COMECE Assembly: EU bishops call for AI to remain at the service of the human person - The Catholic Church in the European Union - October 19th, 2026 [October 19th, 2026]
- Strongly worded U.S. warnings to the European Union regarding restrictions on the technology and satellite markets - - October 19th, 2026 [October 19th, 2026]
- SPCX Stock Down For Third Straight Session: The European Union Is Preparing To Fast Track Approvals For SpaceX's Satellite Rival - Yahoo Finance - October 17th, 2026 [October 17th, 2026]
- Palestine*: Statement by the High Representative on behalf of the European Union on the postponement of elections - Consilium.europa.eu - October 17th, 2026 [October 17th, 2026]
- The European Union Deforestation Regulations Uneven Impact: Who is exposed and what are the costs? - International Institute for Sustainable... - October 17th, 2026 [October 17th, 2026]
- SPCX Stock Down For Third Straight Session: The European Union Is Preparing To Fast Track Approvals For SpaceX's Satellite Rival - Stocktwits - October 17th, 2026 [October 17th, 2026]
- AES wins European Union approval for sale to GIM and EQT Fund Management - Seeking Alpha - October 17th, 2026 [October 17th, 2026]
- COMECE bishops send message of prayer and support to Pope Leo XIV - The Catholic Church in the European Union - October 17th, 2026 [October 17th, 2026]
- AES wins European Union approval for sale to GIM and EQT Fund Management - TradingView - October 17th, 2026 [October 17th, 2026]
- European Union Film Festival launches 29th in-person edition, November 12 to 26 - Stir - October 17th, 2026 [October 17th, 2026]
- Adverse childhood experiences in the European Union, Iceland and Norway: characteristics, consequences and costs - World Health Organization (WHO) - October 10th, 2026 [October 10th, 2026]
- The Vadul Racov bell tower, restored with European Union and UNDP support, inaugurated together with the community - United Nations Development... - October 10th, 2026 [October 10th, 2026]
- Ethiopia: Statement by the High Representative on behalf of the European Union on the escalating conflict in Ethiopia and the implications for the... - October 10th, 2026 [October 10th, 2026]
- European and World Day against the Death Penalty: joint statement by the Secretary General of the Council of Europe and the High Representative of the... - October 10th, 2026 [October 10th, 2026]
- Europe under pressure: what does it need to decide now? - European Union Institute for Security Studies | - October 10th, 2026 [October 10th, 2026]
- European and World Day against the Death Penalty, 10 October 2026: Joint statement by the High Representative of the European Union and the Secretary... - October 10th, 2026 [October 10th, 2026]
- European Union study finds children absorb more wireless radiation than adults across range of 5G frequencies - Environmental Health News - October 10th, 2026 [October 10th, 2026]
- Frontex, EUAA and IOM launch European Union-funded partnership with Ukraine on borders and asylum - Frontex - October 10th, 2026 [October 10th, 2026]
- China and the European Union agreed on these 16 resolutions from their joint Trade Talks in Beijing - The Tanzania Times - October 10th, 2026 [October 10th, 2026]
- Carney says Canada will decide its own partnerships after Trump calls EU proposal laughable - CNBC - September 20th, 2026 [September 20th, 2026]
- Mapped: The European Union in 2026, and Whats Next - Visual Capitalist - September 20th, 2026 [September 20th, 2026]
- State of the European Union 2026: GLOBSEC Experts Weigh In - GLOBSEC - September 20th, 2026 [September 20th, 2026]
- The European Union participates at the launch of the Strategic Plan 20262028 of the African Union Office of the Special Envoy on Women, Peace and... - September 20th, 2026 [September 20th, 2026]
- Carney welcomes proposal for Canada to be European Union's first associate member - Le Monde.fr - September 20th, 2026 [September 20th, 2026]
- Relations with the European Union - North Atlantic Treaty Organization | NATO - September 11th, 2026 [September 11th, 2026]
- Owning the middle: What India's BRICS presidency says about the future of multilateralism - European Union Institute for Security Studies | - September 11th, 2026 [September 11th, 2026]
- A Serbia that mourns Mladi and rallies behind Vui cannot join the European Union - EUobserver - September 8th, 2026 [September 8th, 2026]
- Spanish City Overwhelmed by Moroccan Migrant Influx Pleads For Help From European Union - The New York Sun - September 8th, 2026 [September 8th, 2026]
- International Day Commemorating the Victims of Acts of Violence based on Religion or Belief: Statement by the High Representative on behalf of the... - August 23rd, 2026 [August 23rd, 2026]
- European Union launches a new EUR143 million Annual Action Plan (AAP) 2026 for Malawi - European External Action Service (EEAS) - August 23rd, 2026 [August 23rd, 2026]
- European Union Foreign Policy and the Global Climate Regime - ActuaLitt.com - August 23rd, 2026 [August 23rd, 2026]
- Volodymyr Zelensky requests the European Union for 30 billion euros in aid to finance Ukraine's defense. - Informat.ro - August 23rd, 2026 [August 23rd, 2026]
- Is the U.S. driving Iceland to join the European Union? - DW.com - August 16th, 2026 [August 16th, 2026]
- European Union Brackish Water Reverse Osmosis Systems - Market Analysis, Forecast, Size, Trends and Insights - IndexBox - August 16th, 2026 [August 16th, 2026]
- Uefa takes inspiration from European Union in plan to oust Gianni Infantino and reform Fifa - The Independent - August 16th, 2026 [August 16th, 2026]
- European Union marks International Youth Day in Nepal with a day of opportunity, innovation and youth leadership - EEAS - August 16th, 2026 [August 16th, 2026]
- European Union Indirect Fired Heaters - Market Analysis, Forecast, Size, Trends and Insights - IndexBox - August 16th, 2026 [August 16th, 2026]
- 'Migrant tunnels' used by foreigners to smuggle into European Union exposed as border crisis deepens - GB News - August 11th, 2026 [August 11th, 2026]
- European Union IP Rated Enclosures - Market Analysis, Forecast, Size, Trends and Insights - IndexBox - August 11th, 2026 [August 11th, 2026]
- International Day of the Worlds Indigenous Peoples, 9 August 2026: Statement by the High Representative on behalf of the European Union -... - August 9th, 2026 [August 9th, 2026]
- Gaza: Statement by the High Representative on behalf of the European Union - consilium.europa.eu - August 9th, 2026 [August 9th, 2026]
- On the Anniversary of the 2008 War, the European Union Condemns Russia's Actions in Georgia - sovanews.tv - August 9th, 2026 [August 9th, 2026]
- 'Superauthoritarian Governance': Abolish the European Union, the Sooner the Better - voz.us - August 9th, 2026 [August 9th, 2026]
- Ukraine PM: The European Union has provided an additional 30 million to the Ukraine Energy Support Fund, bringing its total contribution to the Fund... - August 9th, 2026 [August 9th, 2026]
- European Union intensifies its fascist migration policies in wake of Ceuta - World Socialist Web Site - August 9th, 2026 [August 9th, 2026]
- Why heroism alone is not enough for Ukraines accession to the European Union - EUalive - August 9th, 2026 [August 9th, 2026]
- Bialiatski: Joining the European Union is not a question of "I want or I don't want," it's a question of the - - August 9th, 2026 [August 9th, 2026]
- Venezuela: The IRC and the European Union strengthen health and protection response following earthquakes - International Rescue Committee - August 4th, 2026 [August 4th, 2026]
- The Irish Presidency of the Council of the European Union Should Welcome Scrutiny from Academia - Tech Policy Press - August 4th, 2026 [August 4th, 2026]
- Statement by the High Representative on behalf of the European Union on Iran - consilium.europa.eu - August 4th, 2026 [August 4th, 2026]
- The European Union disburses a new tranche of 1.5 billion euros to Egypt - Financial Afrik - August 4th, 2026 [August 4th, 2026]
- European Union to hold emergency talks to address migration crisis in Ceuta - The Indian Awaaz - August 4th, 2026 [August 4th, 2026]
- European Union gives its greenlight to Paramount and Warner's mega merger with some conditions - AP News - July 24th, 2026 [July 24th, 2026]
- The European Union Is Splinteringand Some Say Thats the Only Way to Revive It - WSJ - July 9th, 2026 [July 9th, 2026]
- Competing for inputs: how the European Union can improve critical raw materials supply security - Bruegel - July 9th, 2026 [July 9th, 2026]
- Aidoptation Receives Approval for First Fully Autonomous Driving Tests on Highways in the European Union - Business Wire - July 9th, 2026 [July 9th, 2026]
- 'If Ukraine falls, this will be the end of the European Union and the end of Europe's future' - France 24 - July 6th, 2026 [July 6th, 2026]
- European Union Sensor Protection Tubes - Market Analysis, Forecast, Size, Trends and Insights - IndexBox - July 6th, 2026 [July 6th, 2026]
- European Union Automotive Raindrop Sensor - Market Analysis, Forecast, Size, Trends and Insights - IndexBox - July 6th, 2026 [July 6th, 2026]
- Speech by President Antnio Costa at the opening ceremony of the Irish Presidency of the Council of the European Union - consilium.europa.eu - July 6th, 2026 [July 6th, 2026]
- The future of the European Union's Cohesion Policy in the next Multiannual Financial Framework post-2027 - Committee of the Regions - July 6th, 2026 [July 6th, 2026]
- The thin blue line: the European Union and the future of Lebanons security beyond UNIFIL - PubAffairs Bruxelles - July 6th, 2026 [July 6th, 2026]
- A decade after Brexit, UK voters reflect on decision to break from European Union - PBS - June 24th, 2026 [June 24th, 2026]
- Dispatch from Tivat: What Montenegro still needs to do to join the European Union - Atlantic Council - June 24th, 2026 [June 24th, 2026]
- Representatives Of The Taliban Have Made Their First Official Visit To The European Union - i24NEWS - June 24th, 2026 [June 24th, 2026]